Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PEPD | P12955 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25575137 | 1.00 | PEPD (0.50) | PEPDACEKDM4EHTTSMN1; SMN2 | |
| SCHEMBL7755799 | 1.00 | PEPD (0.50) | PEPDACEKDM4EHTTSMN1; SMN2 | |
| SCHEMBL26181646 | 1.00 | PEPD (0.50) | PEPDACEKDM4EHTTSMN1; SMN2 | |
| SCHEMBL25575142 | 0.95 | KDM4E (0.47) | PEPDKDM4EHTTSMN1; SMN2MEN1 | |
| SCHEMBL16141882 | 0.95 | KDM4E (0.47) | PEPDKDM4EHTTSMN1; SMN2MEN1 | |
| SCHEMBL26839145 | 0.95 | KDM4E (0.47) | PEPDKDM4EHTTSMN1; SMN2MEN1 | |
| SCHEMBL1115372 | 0.95 | KDM4E (0.47) | PEPDKDM4EHTTSMN1; SMN2MEN1 | |
| SCHEMBL18435274 | 0.95 | KDM4E (0.47) | PEPDKDM4EHTTSMN1; SMN2MEN1 | |
| SCHEMBL11400422 | 0.92 | KDM4E (0.46) | PEPDKDM4EHTTSMN1; SMN2MEN1 | |
| SCHEMBL28885167 | 0.92 | KDM4E (0.46) | PEPDKDM4EHTTSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230287365-A1 | COMPOSITIONS AND METHODS FOR DECREASING INFLAMMATION | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230190950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230165970-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | PEPD 35/4885ACE 28/4885KDM4E 4753/4885 |
| US-20230190950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | PEPD 149/4885ACE 1030/4885KDM4E 4734/4885 |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | FCGR3B, ALB, FCGR1A | PEPD 35/4885ACE 28/4885KDM4E 4753/4885 |
| US-20230165970-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | PEPD 149/4885ACE 1030/4885KDM4E 4734/4885 |
| US-20230287365-A1 | COMPOSITIONS AND METHODS FOR DECREASING INFLAMMATION | ENTPD1, ENTPD2, ENTPD5 | PEPD 182/4885ACE 681/4885KDM4E 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.